{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1363670321005596416.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1136/ard.2006.062760"}},{"identifier":{"@type":"URI","@value":"https://api.elsevier.com/content/article/PII:S0003496724346540?httpAccept=text/xml"}},{"identifier":{"@type":"URI","@value":"https://api.elsevier.com/content/article/PII:S0003496724346540?httpAccept=text/plain"}},{"identifier":{"@type":"URI","@value":"https://syndication.highwire.org/content/doi/10.1136/ard.2006.062760"}}],"dc:title":[{"@value":"Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists"}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1380021796600383874","@type":"Researcher","foaf:name":[{"@value":"Johan Askling"}]},{"@id":"https://cir.nii.ac.jp/crid/1380021796600383883","@type":"Researcher","foaf:name":[{"@value":"C Michael Fored"}]},{"@id":"https://cir.nii.ac.jp/crid/1380021796600383873","@type":"Researcher","foaf:name":[{"@value":"Lena Brandt"}]},{"@id":"https://cir.nii.ac.jp/crid/1380021796600383875","@type":"Researcher","foaf:name":[{"@value":"Eva Baecklund"}]},{"@id":"https://cir.nii.ac.jp/crid/1380021796600383876","@type":"Researcher","foaf:name":[{"@value":"Lennart Bertilsson"}]},{"@id":"https://cir.nii.ac.jp/crid/1380021796600383882","@type":"Researcher","foaf:name":[{"@value":"Nils Feltelius"}]},{"@id":"https://cir.nii.ac.jp/crid/1380021796600383886","@type":"Researcher","foaf:name":[{"@value":"Lars Cöster"}]},{"@id":"https://cir.nii.ac.jp/crid/1380021796600383877","@type":"Researcher","foaf:name":[{"@value":"Pierre Geborek"}]},{"@id":"https://cir.nii.ac.jp/crid/1380021796600383881","@type":"Researcher","foaf:name":[{"@value":"Lennart T Jacobsson"}]},{"@id":"https://cir.nii.ac.jp/crid/1380021796600383885","@type":"Researcher","foaf:name":[{"@value":"Staffan Lindblad"}]},{"@id":"https://cir.nii.ac.jp/crid/1380021796600383878","@type":"Researcher","foaf:name":[{"@value":"Jörgen Lysholm"}]},{"@id":"https://cir.nii.ac.jp/crid/1380021796600383879","@type":"Researcher","foaf:name":[{"@value":"Solbritt Rantapää-Dahlqvist"}]},{"@id":"https://cir.nii.ac.jp/crid/1380021796600383884","@type":"Researcher","foaf:name":[{"@value":"Tore Saxne"}]},{"@id":"https://cir.nii.ac.jp/crid/1380021796600383872","@type":"Researcher","foaf:name":[{"@value":"Ronald F van Vollenhoven"}]},{"@id":"https://cir.nii.ac.jp/crid/1380021796600383880","@type":"Researcher","foaf:name":[{"@value":"Lars Klareskog"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"00034967"}],"prism:publicationName":[{"@value":"Annals of the Rheumatic Diseases"}],"dc:publisher":[{"@value":"Elsevier BV"}],"prism:publicationDate":"2007-10","prism:volume":"66","prism:number":"10","prism:startingPage":"1339","prism:endingPage":"1344"},"reviewed":"false","dc:rights":["https://www.elsevier.com/tdm/userlicense/1.0/","https://www.elsevier.com/legal/tdmrep-license"],"url":[{"@id":"https://api.elsevier.com/content/article/PII:S0003496724346540?httpAccept=text/xml"},{"@id":"https://api.elsevier.com/content/article/PII:S0003496724346540?httpAccept=text/plain"},{"@id":"https://syndication.highwire.org/content/doi/10.1136/ard.2006.062760"}],"createdAt":"2007-02-02","modifiedAt":"2025-01-06","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360011143507396736","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: Postmarketing surveillance report of 7740 patients"}]},{"@id":"https://cir.nii.ac.jp/crid/1360021390582256512","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Evaluation of the Rheumatoid Arthritis Observation of Biologic Therapy risk score in Japanese patients with rheumatoid arthritis starting first biologic disease–modifying antirheumatic drugs: A validation study using the Institute of Rheumatology, Rheumatoid Arthritis cohort data"}]},{"@id":"https://cir.nii.ac.jp/crid/1360021390583262848","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Incidence of severe infection in patients with rheumatoid arthritis taking biologic agents: a systematic review"}]},{"@id":"https://cir.nii.ac.jp/crid/1360285704848155520","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Time‐dependent increased risk for serious infection from continuous use of tumor necrosis factor antagonists over three years in patients with rheumatoid arthritis"}]},{"@id":"https://cir.nii.ac.jp/crid/1360567182431352320","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Consensus statements for medical practice: Biological agents and lung disease [Abridged English translation by the Japanese Respiratory Society]"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1136/ard.2006.062760"},{"@type":"CROSSREF","@value":"10.1002/acr.21666_references_DOI_9RZ68omLLijmnkS3vPyw7kY8g4x"},{"@type":"CROSSREF","@value":"10.1093/mr/road066_references_DOI_9RZ68omLLijmnkS3vPyw7kY8g4x"},{"@type":"CROSSREF","@value":"10.11124/jbies-22-00048_references_DOI_9RZ68omLLijmnkS3vPyw7kY8g4x"},{"@type":"CROSSREF","@value":"10.1007/s10165-011-0541-5_references_DOI_9RZ68omLLijmnkS3vPyw7kY8g4x"},{"@type":"CROSSREF","@value":"10.1016/j.resinv.2017.01.002_references_DOI_9RZ68omLLijmnkS3vPyw7kY8g4x"}]}